Stockscreener 앱 받기
1.24
0.72%
-0.01
전일 마감가:
$1.25
열려 있는:
$1.27
하루 거래량:
44,453
Relative Volume:
0.04
시가총액:
$72.50M
수익:
$54.77M
순이익/손실:
$15.24M
주가수익비율:
5.0903
EPS:
0.2436
순현금흐름:
$7.24M
1주 성능:
+9.82%
1개월 성능:
+0.89%
6개월 성능:
-48.51%
1년 성능:
-36.03%
1일 변동 폭
$1.24
$1.29
1주일 범위
$1.12
$1.44
52주 변동 폭
$1.08
$3.08
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
1.245 | 72.79M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
521.26 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.50 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.78 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.03 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.36 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
H.C. Wainwright raises Spero Therapeutics price target to $6 By Investing.com - Investing.com Nigeria
SPROSpero Therapeutics Inc Short Interest - Finviz
Spero Therapeutics, Inc. SEC Filing (Sep 11, 2026) - Stock Titan
Spero Therapeutics (SPRO) 10K Form and Latest SEC Filings 2026 - marketbeat.com
Spero Therapeutics Inc. (SPRO) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New employees get stock awards at Spero, unlocking from 2027 - Stock Titan
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A biotech CEO will speak in New York Sept. 15. Spero will stream it. - Stock Titan
Spero Therapeutics stock gains on small-cap biotech interest - ad-hoc-news.de
Spero Therapeutics Inc. (SPRO) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1 - ad-hoc-news.de
Spero Therapeutics Inc (SPRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Spero Therapeutics Launches New ATM Program With Jefferies for Up to $100 Million - TradingView
Spero TherapeuticsMay Offer Up To $300 Million In SecuritiesSEC Filing - tradingview.com
Spero Therapeutics Company Profile & Introduction - Moomoo
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript - AOL.com
Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO - MarketBeat
Spero Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US84833T1034 - marketscreener.com
Diluted shares outstanding of Spero Therapeutics, Inc. – BIVA:SPRO - TradingView
Long term debt to total assets ratio of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Net current asset value per share of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights - GuruFocus
SPRO Looks 14.8% Overvalued on GF Value™ as FDA Approval Spurs I - GuruFocus
Spero Therapeutics Q2 Earnings Call Highlights - MarketBeat
SPRO: FDA approval, immunology pivot, and $105M financing extend cash runway into 2029 - TradingView
Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Is Spero Therapeutics Inc (SPRO) a Smart Investment Post Q2 Earnings? GF Score: 69/100, 13.3% Overvalued - GuruFocus
SPRO: FDA approval of Utebzi and $105M financing position the company for long-term growth - tradingview.com
Spero Therapeutics 2Q 2026: Revenue $0M, EPS $(0.16) — 10-Q Summary - TradingView
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Spero Therapeutics (SPRO) Slips to $1.26: Stock Holds Tight Range Between $1.20 Support and $1.32 ResistanceThematic ETF Flow - vinanet.vn
Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Equity awards for Spero Therapeutics (SPRO) chief medical officer - Stock Titan
Spero Therapeutics CMO Debra Zack files initial beneficial ownership statement - Bitget
SPRO Q2'26 Earnings: EPS estimate is (0.17) USD - TradingView
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - The Manila Times
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update ... - Caledonian Record
Spero Therapeutics to discuss drug pipeline on Aug. 12 - Stock Titan
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Spero Therapeutics (SPRO) Holds Steady at $1.17 as Shares Consolidate in a Tight RangeHigh Volume Stocks - dars.gov.et
Spero Therapeutics, Inc. Revenue Breakdown – NASDAQ:SPRO - TradingView
SPRO|Spero Therapeutics Inc|Price:1.170|Chg%:-0.020 - TradingKey
Spero Therapeutics Appoints Dr. Debra Jeske Zack Chief Medical Officer to Lead SP001 Development - citybiz.co
Spero Therapeutics names Debra Zack as chief medical officer - Investing.com
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.36%
자본화:
|
볼륨(24시간):